Close Menu

NEW YORK (360Dx) – Today's World Health Organization's prequalification of OraSure Technologies' HIV self-test could reinforce international demand that's already driving sales growth for the test, according to an investment analyst.    

"With prequalification in hand, we expect ordering for the HIV self-test to begin picking up from the many countries with whom OraSure has been in dialogue," Mark Massaro, an analyst at Canaccord Genuity investment bank, said in an interview.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.